Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Balance Sheets

v3.26.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Assets    
Cash and cash equivalents $ 1,303 $ 5,343
Prepaid expenses and other current assets 676
Current assets held for sale 26,930 26,822
Total Current assets 28,909 32,165
Investment in DNA X, LLC 1,242
Deferred tax assets 1,441 64
Other assets 274 384
Non-current assets held for sale 12,032 7,126
Total assets 43,898 39,739
Liabilities and stockholders’ deficit    
Accounts payable 4,030 738
Accrued liabilities 704 250
Promissory notes, net 5,065
Derivative liability on convertible note 171
Current liabilities held for sale 38,057 42,752
Total current liabilities 48,027 43,740
Income tax payable 2,598 1,699
Total liabilities 50,625 45,439
Commitments and contingencies (Note 9)
Redeemable common stock, $0.001 par value; 223,201 shares issued and outstanding; redemption value $1,228 (Note 6) 1,228
Stockholders’ deficit    
Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,265,067 and 276,881 shares issued and outstanding at December 31, 2025 and 2024, respectively [1] 1
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at December 31, 2025 and 2024
Additional paid-in capital [1] 296,309 277,908
Accumulated deficit (304,265) (283,608)
Total stockholders’ deficit (7,955) (5,700)
Total liabilities, redeemable common stock, and stockholders’ deficit $ 43,898 $ 39,739
[1] Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025, see Note 1.